Trials / Completed
CompletedNCT00751764
Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women
An Open-Label, Single-Dose Study to Evaluate the Excretion of Moxidectin Into the Breast Milk of Lactating, Non-breastfeeding Women.
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- Female
- Age
- 21 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the extent of moxidectin transfer into the breast milk of lactating women and to provide the initial pharmacokinetic and safety profile of moxidectin in lactating women.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxidectin |
Timeline
- Start date
- 2008-11-01
- Primary completion
- 2009-09-01
- Completion
- 2009-09-01
- First posted
- 2008-09-12
- Last updated
- 2010-09-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00751764. Inclusion in this directory is not an endorsement.